In Development

Our goal is to help turn lung cancer into a chronically managed disease as rapidly as possible, and to that end we are developing cutting-edge collaborations among and between academia, community centers, diagnostics laboratories and bio-pharmaceutical companies. ALCMI is actively co-developing patient-centric studies in the following areas:

  • Blood-based diagnostic and predictive clinical laboratory testing
  • Epidemiology of Young Lung Cancer
  • Small Cell Lung Cancer
    • PD-1/IDO1 clinical trial
  • Immuno-oncology
    • targeting lung cancer stem cells
    • lung cancer therapeutic vaccine development
    • Phase II combination clinical trial
  • Improving Lung Cancer Treatment and Survival Through Genomics (Ohio)

For collaboration queries, please contact:

Tony Addario
Chair & CEO
Addario Lung Cancer Medical Institute
Office: (650) 598-2857
[email protected]